VBI Vaccines (VBIV) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
At VBI Vaccines’ Annual General Meeting, shareholders represented nearly half of the company’s outstanding shares, reaffirming their support by re-electing all eight director nominees with a high percentage of votes in favor. Additionally, the shareholders voted to appoint EisnerAmper LLP as the independent registered public accounting firm for the upcoming year. VBI Vaccines continues to focus on powerful disease prevention and treatment, leveraging its innovative virus-like particle technologies.
For further insights into VBIV stock, check out TipRanks’ Stock Analysis page.